These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36894873)

  • 41. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy.
    Kersh AE; Schuchter LM; Elenitsas R; Chu EY
    Immunotherapy; 2020 Sep; 12(13):951-956. PubMed ID: 32772616
    [No Abstract]   [Full Text] [Related]  

  • 44. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
    Abe K; Ishikawa Y; Fujiwara M; Yukawa H; Yanagihara T; Takei S; Arioka H; Kita Y
    Medicine (Baltimore); 2022 Jan; 101(2):e28428. PubMed ID: 35029182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vasculitis of small muscular arteries, activation of vessel-infiltrating CD8 T cells seems to be antigen-independent.
    Kobayashi M; Ogawa E; Okuyama R; Kanno H
    Virchows Arch; 2018 Feb; 472(2):271-279. PubMed ID: 29128969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma.
    Singh P; Wolfe SP; Alloo A; Gottesman SP
    J Cutan Pathol; 2020 Jan; 47(1):65-69. PubMed ID: 31390071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
    Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis.
    Hakroush S; Tampe B
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769297
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute interstitial nephritis related to immune checkpoint inhibitors.
    Belliere J; Meyer N; Mazieres J; Ollier S; Boulinguez S; Delas A; Ribes D; Faguer S
    Br J Cancer; 2016 Dec; 115(12):1457-1461. PubMed ID: 27832664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute kidney injury from immune checkpoint inhibitor use.
    Gordon L; Dokouhaki P; Hagel K; Prasad B
    BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31653633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
    Das S; Johnson DB
    J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of checkpoint inhibitor-induced celiac disease.
    Alsaadi D; Shah NJ; Charabaty A; Atkins MB
    J Immunother Cancer; 2019 Aug; 7(1):203. PubMed ID: 31383006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
    Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
    Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes of responders to PD-1/PD-L1 inhibitors who discontinue therapy after sustained disease control.
    Sharma H; Moturi KR; Pankratz VS; Yilmaz E; Gbolahan OB; Kumar A; Hashemi-Sadraei N
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8673-8680. PubMed ID: 37115270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.